Learning objectives
To provide a basic understanding of CCT technology and use of different scan protocols according to the clinical questions
To describe what information can be obtained from a CCT study for a variety cardiac conditions and how this can affect clinical management
To know indications for CCT for the different cardiac conditions and how this is reflected in current ESC guidelines and recommendations.
Access publication
This 2026 EACVI/ESC clinical consensus statement provides a broad practical framework for cardiac CT (CCT), but importantly identifies photon-counting detector CT (PCD-CT/PCCT) as the latest major technological advance in cardiac CT. The central advantage of PCCT is the substantial improvement in spatial resolution: whereas conventional 64-slice, dual-source, and wide-coverage systems generally remain around 0.5–0.6 mm, PCCT can achieve spatial resolution down to approximately 0.2 mm. At the same time, contemporary photon-counting systems can retain the high temporal-resolution advantages associated with dual-source technology.
Why PCCT matters clinically
The increased spatial resolution is particularly relevant where conventional CCTA is limited by very small structures or high-attenuation material. The consensus specifically highlights heavily calcified coronary lesions, assessment of in-stent restenosis (ISR), and detection of myocardial injury as promising applications. This is clinically important because coronary stent assessment remains substantially more difficult than evaluation of native coronary arteries, while heavily calcified native vessels—particularly in previously revascularized patients—can also be challenging with conventional CCTA.
Thus, PCCT is positioned less as a completely different cardiac CT examination than as a technological refinement of CCTA that may extend diagnostic performance into situations traditionally limited by spatial resolution. The potential value is especially intuitive for coronary lumen evaluation adjacent to calcium or metallic stent struts, where conventional CT has difficulty resolving small residual luminal dimensions.
PCCT examination / acquisition considerations
The general cardiac CT principles remain applicable: acquisition is ECG-synchronized to minimize cardiac-motion artefacts and requires a short 5–10 s breath-hold. CCTA requires intravenous iodinated contrast, whereas coronary calcium scoring is performed without contrast.
For coronary imaging, careful heart-rate control remains important even with advanced CT technology. High heart rate, heart-rate variability, obesity, and respiratory motion impair interpretability. Unless contraindicated, the document recommends pharmacological heart-rate reduction toward ≤60 bpm, using agents such as beta-blockers or ivabradine; sublingual nitroglycerin approximately 5 min before CCTA improves coronary vasodilatation and visualization of peripheral coronary segments.
A key PCCT-specific trade-off is that its ultra-high-resolution mode still requires acquisition over multiple heartbeats. Consequently, the maximum spatial-resolution capability of PCCT does not eliminate the importance of rhythm stability and motion control. In other words, the ≈0.2-mm resolution represents a major improvement in spatial resolution, but ultra-high-resolution coronary PCCT does not necessarily provide single-heartbeat acquisition.
Radiation and reconstruction
The consensus emphasizes maintaining the ALARA principle. Contemporary CT dose-reduction approaches include prospective ECG triggering, high-pitch acquisition, tube-current/voltage modulation, low-kV protocols, iterative or deep-learning reconstruction, faster rotation, and motion-correction techniques. Across modern CCT generally, typical effective doses are around 3 mSv and can fall below 1 mSv with the latest technologies, although the document does not provide a separate PCCT-specific dose figure for ultra-high-resolution coronary acquisitions.
PCCT datasets can be evaluated with the usual cardiac CT post-processing tools—including axial images, MPR/cMPR, MIP, and volume rendering—with the increased intrinsic spatial resolution providing the principal technical advantage.
Clinical perspective
The consensus therefore presents PCCT as a particularly promising next step for high-resolution coronary imaging, potentially addressing some of the hardest problems for conventional CCTA: dense coronary calcium, small coronary structures and stented segments. However, it stops short of establishing PCCT as a new evidence-based standard for these indications. The authors explicitly note that intra-patient randomized controlled trials are still lacking, so the technological advantages and encouraging early clinical applications currently exceed the level of definitive comparative outcome evidence.
Take-home: PCCT pushes cardiac CT spatial resolution from roughly 0.5–0.6 mm toward 0.2 mm, with the greatest expected benefit in calcified coronary disease and stent imaging. The price of maximal ultra-high resolution is currently multi-beat acquisition, making excellent ECG synchronization, low/stable heart rate and breath-holding particularly important. The 2026 EACVI/ESC consensus views the technology as highly promising, but not yet supported by definitive randomized comparative evidence.
